Suggestions
Dmitry Kalupin
Digital models of immune cells, driven by spatial and single-cell transcriptomics
Dmitry Kalupin is a visionary leader in the field of artificial intelligence and biotechnology. With a robust background in strategy, innovation, and management control, Dmitry is dedicated to the advancement of healthcare through the development of large-scale AI models that replicate human cellular functions. His passion lies in transforming medical treatments by creating highly specific and non-toxic therapies that can revolutionize the healthcare industry and ultimately, enhance the well-being and longevity of individuals. By leveraging cutting-edge research and technology, including single-cell RNA sequencing and spatially resolved transcriptomics, Dmitry is at the forefront of building digital models that not only empower researchers but also unlock the potential to find cures for currently intractable disorders.
Dmitry's approach to healthcare extends beyond just treating diseases; he is committed to a deeper understanding of life's building blocks that could lead to groundbreaking discoveries in medicine. His work encompasses developing an end-to-end framework designed to predict changes in the transcriptome of human cells, showcasing his innovative thinking and commitment to scientific excellence. These predictive models are a groundbreaking innovation, significantly enhancing the accuracy of therapeutic interventions, thus leading to a higher probability of success in subsequent in-vivo experiments. This transformational impact on research methodologies holds the promise of saving trillions of dollars globally, underscoring the importance of Dmitry’s contributions to the medical and scientific communities.
Dmitry's educational journey is impressive, having studied Strategy, Innovation, and Management Control at the esteemed WU (Vienna University of Economics and Business). This academic foundation is complemented by his studies in International Business at the Graduate School of Management at St. Petersburg State University, as well as his Specialist Graduate Degree in Mathematics from the same institution. This rich educational background equips him with a unique blend of analytical and strategic skills, essential for navigating the complexities of technology and healthcare innovation.
Dmitry's professional trajectory exhibits a strong entrepreneurial spirit and a commitment to excellence. He has been instrumental in founding and leading several innovative companies, including Unlock Biology, which focuses on groundbreaking biotechnology solutions. His experience as a Fellow at the Startup Leadership Program highlights his dedication to fostering new ideas and supporting the startup ecosystem. Dmitry has also showcased his leadership capabilities as the founder of Friday Software and FriendZone, where he applied his strategic vision and innovative mindset to drive growth and success.
His diverse work experience includes roles such as a Quantitative Trader and Special Projects Manager at Quantum Brains, where he demonstrated his analytical prowess and ability to manage complex projects. Dmitry's role as a Discussion Host at GranumSalis further illustrates his commitment to knowledge sharing and collaboration within the tech community. His previous experiences as Marketing Director at Belkasoft, Project Lead at Expolet, and Management Consultant at ALT Research & Consulting illustrate his versatility and capability in various domains, contributing to his comprehensive understanding of both technology and business.
Additionally, Dmitry has served as Project Lead at Computer Vision Tech and Sales Manager at eLama, where he honed his skills in project management and sales strategy. His experience as a Software Test Engineer for Sun Microsystems (Oracle) at Oracle, as well as at Smartphone Labs, adds a strong technical foundation to his extensive resume. Overall, Dmitry Kalupin's career is characterized by a blend of entrepreneurial ventures, leadership roles, and a persistent commitment to advancing healthcare technologies through innovation and collaboration.
